Equity strategies

Carmignac Portfolio Investissement

Luxembourg SICAV sub-fundGlobal marketSRI Fund Article 8
Share Class

LU1299311164

A Fund geared for a changing world
  • An international equity Fund offering an exposure to companies that thrive in an evolving global world.
  • An opportunistic approach aiming at benefiting from the most promising market dynamics and trends.
Key documents
Asset Allocation
Equities97.7 %
Other2.3 %
Data as of:  30 Sep 2024.
Risk Indicator
4/7
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
+ 88.2 %
0.0 %
+ 80.3 %
+ 14.2 %
+ 27.7 %
From 19/11/2015
To 10/10/2024
Calendar Year Performance 2023
-
- 1.7 %
+ 2.1 %
+ 4.7 %
- 14.0 %
+ 25.1 %
+ 34.6 %
+ 4.5 %
- 17.9 %
+ 19.4 %
Net Asset Value
188.21 €
Asset Under Management
250 M €
Market
Global market
SFDR - Fund Classification

Article

8
Data as of:  10 Oct 2024.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.

Carmignac Portfolio Investissement fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  30 Sep 2024.
Fund management team

Kristofer Barrett

Head of Global Equities, Fund Manager

Market environment

  • Major indices reached all-time highs during the month, driven by monetary easing from central banks.

  • Chinese equities surged towards the end of the period as Beijing's stimulus measures boosted optimism about the recovery of the world's second-largest economy. These measures aim to counter monetary contraction, address the collapse in the property market, and revive the struggling stock market.

  • The Federal Reserve initiated its easing cycle with an aggressive 50 basis point cut in its key rate, while the European Central Bank continued to reduce its key rates by 25 basis points.

  • Economic indicators in the United States remain robust, with rising retail sales and industrial production, a mixed but solid employment market, and falling inflation. In contrast, economic activity in the eurozone has been more lackluster.

Performance commentary

  • The Fund posted a negative performance in September, penalized by the underperformance of several stocks in the portfolio.

  • Novo Nordisk was the most significant detractor. The stock faced multiple negative developments, including potential competition for its weight loss and diabetes drugs, pricing concerns in the US, and disappointing results from its weight loss pill currently in development.

  • Samsung Electronics also negatively impacted performance, as it was outperformed by its rival SK Hynix in the artificial intelligence memory chip sector.

  • Conversely, our investments in Taiwan (TSMC) and China (VIP Shop) contributed positively to the Fund's performance.

Outlook strategy

  • We maintain a positive outlook on equities. In a context of gradual economic slowdown and global monetary easing, risky assets are expected to perform well, provided there is no recession.

  • Our portfolio strategy is balanced, integrating high-growth equities with relatively high valuations alongside lower-growth equities that offer high visibility and attractive valuations.

  • Our top picks include Synopsys and Cadence, whose software is utilized by chipmakers like Nvidia for designing and testing processors. These companies are also experiencing growth driven by the increasing interest from firms such as Microsoft and Google in developing their own chips, particularly for artificial intelligence applications.

  • We are progressively increasing our exposure to small- and mid-cap companies, which allows us to further diversify our portfolio.

Performance Overview

Data as of:  10 Oct 2024.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
Source: Carmignac at 13/10/2024

Carmignac Portfolio Investissement Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  30 Sep 2024.
North America62.8 %
Asia19.9 %
Europe12.9 %
Latin America2.5 %
Asia-Pacific2.0 %
Total % Equities100.0 %
North America62.8 %
usUSA
60.6 %
caCanada
2.2 %

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  30 Sep 2024.
Equity Investment Weight97.7 %
Net Equity Exposure90.6 %
Number of Equity Issuers72
Active Share80.4 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Manager.
Fund Management Team

Kristofer Barrett

Head of Global Equities, Fund Manager
Since its creation in 1989 by Edouard Carmignac, our Investissement strategy seeks to identify long-term trends in a changing world and seize global equity market opportunities.
View Fund's characteristics
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
​The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.

Related articles

[Background image] [CI] Blue sky and buildings
Global equities2 July 2024English

Exploring the benefits of Carmignac Investissement

2 minute(s) read
Find out more